Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly
05:14pm, Friday, 23'rd Dec 2022 Zacks Investment Research
ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.
MGV: Mega Cap Value ETF, Wrap It Up And Put A Bow On Top
05:23am, Friday, 23'rd Dec 2022 Seeking Alpha
The Vanguard Mega Cap Value ETF has outperformed the S&P 500 by ~16% over the past year. Read why I feel MGV ETF is very attractive.
The Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly
03:53pm, Thursday, 22'nd Dec 2022 Zacks Investment Research
United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly are part of the Zacks top Analyst Blog.
Stocks remain overpriced, even vs. the dot-com bubble. But you can still find good picks in these 2 sectors.
02:54pm, Thursday, 22'nd Dec 2022 MarketWatch
For investors not cowed by this year and ready to look ahead at where some gains may come from, we've got a couple ideas from the son of a legendary investor.
Has This Top Pharma Company Found Its Next Billion-Dollar Product?
02:53pm, Thursday, 22'nd Dec 2022 The Motley Fool
Eli LIlly is looking to make waves in an important therapeutic area.
Roche (RHHBY) Actemra Gets FDA Nod for Adults With COVID-19
01:52pm, Thursday, 22'nd Dec 2022 Zacks Investment Research
Roche (RHHBY) obtains FDA approval for Actemra (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adult patients. The drug was earlier granted an EUA.
Has This Top Pharma Company Found Its Next Billion-Dollar Product?
09:53am, Thursday, 22'nd Dec 2022
Eli LIlly is looking to make waves in an important therapeutic area.
ProQR's stock jumps on expanded RNA deal with Lilly
09:12am, Thursday, 22'nd Dec 2022
Shares of ProQR Therapeutics NV PRQR, +1.85% soared 56.3% in premarket trading on Thursday after the company said it expanded an RNA editing deal with Eli Lilly & Co. Inc. LLY, +2.33% aimed at making
3 Drug Stocks Most Wall Street Analysts Are Bullish About
02:51pm, Wednesday, 21'st Dec 2022 Zacks Investment Research
Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro e
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
08:00pm, Tuesday, 20'th Dec 2022 Benzinga
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) has announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom.
JMP has raised the price target from $182 to $31
Jim Cramer says these 7 stocks will be winners in 2023
06:31pm, Tuesday, 20'th Dec 2022
Cramer said many of Wall Street's concerns about the market are overblown.
Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?
02:30pm, Tuesday, 20'th Dec 2022 Zacks Investment Research
Based on the average brokerage recommendation (ABR), Lilly (LLY) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this hig
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
11:20am, Tuesday, 20'th Dec 2022 Zacks Investment Research
Sector ETF report for PPH
Eli Lilly (LLY) Stock Moves -0.58%: What You Should Know
10:45pm, Monday, 19'th Dec 2022 Zacks Investment Research
In the latest trading session, Eli Lilly (LLY) closed at $357.78, marking a -0.58% move from the previous day.
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
01:35pm, Monday, 19'th Dec 2022
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum
